Risks involved with outsourcing pharmaceutical development overseas have become greater with the disruptions caused by the COVID-19 pandemic and global political rivalries, underscoring the need for therapy and vaccine-makers to consider their partnerships carefully. Shortages of raw materials, delays in delivering active pharmaceutical ingredients (APIs), and sometimes-severe quality issues have made more developers turn to work with US-based business partners.
Synergy Bioscience facilities are based in the United States and are cGMP (current Good Manufacturing Practices) certified and accredited by the U.S. Food and Drug Administration and A2LA, among others. Through these regulatory requirements as well as Synergy’s own robust quality system, we can guarantee the safety, quality, and integrity of your products, so you can focus on creating new generations of life-saving drugs and vaccines.